<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2018 [PPXK5GW761L0VLMCFLA5]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=center style='font:10pt Times New Roman;margin:0'>UNITED STATES<BR>SECURITIES AND EXCHANGE COMMISSION<BR>Washington, D.C. 20549</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>FORM 8-K</B></P>
<P align=center style='font:10pt Times New Roman;margin-top:24pt;margin-bottom:0pt;color:#000000'><B>CURRENT REPORT</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>Date of Report (Date of earliest event reported): January 17, 2019 </P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>NEWBRIDGE GLOBAL VENTURES, INC.</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>(Exact Name of Registrant as Specified in its Charter)</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<TABLE align=center style=border-collapse:collapse><TR><TD valign=top style=width:170.95pt;padding:0.75pt><P align=center style='font:10pt Times New Roman;margin:0'>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<B>Delaware&#160;&#160;&#160;&#160;&#160;&#160;&#160;</B></P>
</TD><TD valign=top style=width:126.05pt;padding:0.75pt><P align=center style='font:10pt Times New Roman;margin:0'><B>0-11730</B></P>
</TD><TD valign=top style=width:139.5pt;padding:0.75pt><P align=center style='font:10pt Times New Roman;margin:0'><B>84-1089377</B></P>
</TD></TR>
<TR><TD valign=top style=width:170.95pt;padding:0.75pt><P align=center style='font:10pt Times New Roman;margin:0'>(State or other jurisdiction<BR>of incorporation)</P>
</TD><TD valign=top style=width:126.05pt;padding:0.75pt><P align=center style='font:10pt Times New Roman;margin:0'>Commission File<BR>Number</P>
</TD><TD valign=top style=width:139.5pt;padding:0.75pt><P align=center style='font:10pt Times New Roman;margin:0'>(I.R.S. Employer Identification number)</P>
</TD></TR>
</TABLE>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'><B>2545 Santa Clara Avenue</B></P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'><B>Alameda, CA 94501</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Address of Principal Executive Offices)&#160;&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>801-362-2115</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>(Registrant&#8217;s Telephone Number, Including Area Code)</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0'>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>
<P style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style=font-family:Wingdings>&#111;</FONT>&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
<P style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style=font-family:Wingdings>&#111;</FONT>&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
<P style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style=font-family:Wingdings>&#111;</FONT>&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
<P style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style=font-family:Wingdings>&#111;</FONT>&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
<P style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:10pt;margin-left:72pt;color:#000000'>&#160;</P>
<HR style='page-break-after:always;border:0;height:3.75pt;background-color:#919191;margin:15pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'><B>Item 1.01. &#160;Entry into a Material Definitive Agreement</B></P>
<P style='font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'><KBD style=margin-left:36pt></KBD>The information furnished in Item 5.02 herein is hereby incorporated by reference into this Item 1.01 &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'><B>Item 5.02. &#160;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers  </B></P>
<P style='font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'><KBD style=margin-left:36pt></KBD>On January 17, 2019 the Board of Directors of NewBridge Global Ventures, Inc. (the &#8220;Company&#8221;) determined to appoint Dr. John MacKay as Chief Technology Officer (&#8220;CTO&#8221;) of the Company, Patrick P. Tang as Chief Compliance Officer (&#8220;CCO&#8221;) of the Company and Sandra Ribble as Corporate Controller of the Company. &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'><KBD style=margin-left:36pt></KBD>Dr. John A. MacKay in his position as Chief Technology Officer (&#8220;CTO&#8221;) shall be an executive officer of the Company. John is the founder and President of Synergistic Technologies Associates, LLC a consulting company that works with botanical companies to help maximize their total operations based on Six Sigma principles and practices. He also serves as contributing journalist and science editor for Terpenes and Testing Magazine and was the editor of the early issues of Extraction Magazine and now is contributing journalist and scientific advisor. &nbsp;He has also been appointed the Educator Assistant Professor on the Volunteer Pathway, Department of Pharmacology at the Robert Larner, MD College of Medicines. John A. MacKay earned a B.A. in Chemistry from St. Lawrence University (SLU), and Ph.D. from the University of Vermont (UVM), in Inorganic Chemistry focused on the synthesis of cancer-fighting compounds. &nbsp;After positions teaching at Davidson College, Lyndon State College and University of Vermont (UVM), John joined Waters Corporation in 1983 and retired in 2017. &nbsp;His career has included many roles in innovative product development and marketing. &nbsp;John is widely recognized as scientific expert extraction with an emphasis on the sub and supercritical fluid for extraction and chromatography in the botanical space; he is bringing the synergy from what were disparate technologies together to optimize workflow. Pursuant to his employment agreement, Dr. MacKay shall receive an annual salary of $10,000 per month, a sign-on bonus of 200,000 shares of the Company&#8217;s common stock, options to acquire 1,000,000 shares of the Company&#8217;s common stock at an exercise price of $1.00 per share, and will be eligible for annual variable compensation. The foregoing is qualified in its entirety by reference to the employment agreement between Dr. MacKay and the Company which is attached hereto as Exhibit 10.1 &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'><KBD style=margin-left:36pt></KBD>Mr. Patrick Tang, in his position of Chief Compliance Officer (&#8220;CCO&#8221;) shall be an executive officer of the Company. Mr. Tang has over 28 years of experience in the business management and operations of public and private companies. Prior to joining NewBridge Global Ventures, Mr. Tang has served as a Sales and Business Development Executive at MacDermidAlpha-Compugraphics, and an Executive Advisor at TCE Group, a contract manufacturing services for microelectronics industry. &nbsp;From 2016 to 2018, Mr. Tang served as Vice President of Sales and Business Development at Advenira, Inc., a developer of nanocomposite. From 2014 to 2016, he also served as Director of Business Development and Application Engineering at Aculon, Inc, a nanomaterial company focusing on microelectronics, wireless, oil &amp; gas, IoT, and medical devices applications. Prior to Aculon, he served as Director of Product Technology Marketing at JCET, tier 1 semiconductor packaging, assembly and test. &nbsp;Mr. Tang is a licensed Professional Chemical Engineer and holds an MBA from the University of San Francisco with technical training in chemistry, chemical engineering and microelectronics. Pursuant to his employment agreement, Mr. Tang shall receive a salary of $10,000 per month from March 2019 through December 2019 and $15,000 per month for the twelve months ending December 2020, options to acquire 300,000 shares of the Company&#8217;s common stock to vest over three years at an exercise price of $1.00 per share, and will be eligible for annual variable compensation. The foregoing is qualified in its entirety by reference to the employment agreement between Mr. Tang and the Company which is attached hereto as Exhibit 10.2&nbsp;</P>
<HR style='page-break-after:always;border:0;height:3.75pt;background-color:#919191;margin:15pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'><KBD style=margin-left:36pt></KBD>A copy of the Company&#8217;s press release relating to these changes is being furnished as Exhibit 99.1 to this Current Report on&#160;Form&#160;8-K.&#160;Exhibit 99.1 shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'><B>Item 9.01. &#160;Financial Statements and Exhibits.</B></P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:121.5pt;color:#000000'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>The exhibits listed below are furnished as Exhibits to this Current Report on Form 8-K.</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</P>
<TABLE align=center style=border-collapse:collapse;width:469.5pt><TR style=height:10.8pt><TD valign=middle style=width:59.25pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0;color:#000000'>Exhibit No.</P>
</TD><TD valign=middle style=width:410.25pt;white-space:nowrap;padding:0.75pt><P style='font:10pt Times New Roman;margin:0;color:#000000'>Description</P>
</TD></TR>
<TR style=height:10.8pt><TD valign=middle style=width:59.25pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0;color:#000000'>10.1</P>
</TD><TD valign=middle style=width:410.25pt;white-space:nowrap;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'><A href=nbgv_ex10z1.htm style=text-decoration:none><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'>Employment Agreement with Dr. John MacKay</FONT></A></P>
</TD></TR>
<TR style=height:10.8pt><TD valign=middle style=width:59.25pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0;color:#000000'>10.2</P>
</TD><TD valign=middle style=width:410.25pt;white-space:nowrap;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'><A href=nbgv_ex10z2.htm style=text-decoration:none><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'>Employment Agreement with Patrick T. Tang</FONT></A> </P>
</TD></TR>
<TR style=height:10.8pt><TD valign=middle style=width:59.25pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0;color:#000000'>99.1&#160;</P>
</TD><TD valign=middle style=width:410.25pt;white-space:nowrap;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'><A href=nbgv_ex99z1.htm style=text-decoration:none><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'>Press Release, dated January 17, 2018</FONT></A> </P>
</TD></TR>
<TR style=height:10.8pt><TD valign=middle style=width:59.25pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style=width:410.25pt;white-space:nowrap;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0;margin-left:72pt;color:#4F81BD'>&#160;</P>
<HR style='page-break-after:always;border:0;height:3.75pt;background-color:#919191;margin:15pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0;color:#4F81BD'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:10pt;color:#000000'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'><B>SIGNATURES</B></P>
<P style='font:10pt Calibri;margin-top:0pt;margin-bottom:10pt'><FONT style='font-family:Times New Roman'>&#160;</FONT></P>
<P style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:10pt'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>
<P style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:10pt'>&#160;</P>
<TABLE align=center style=border-collapse:collapse><TR><TD valign=top style=width:32.4pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD><TD valign=top style=width:207pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD><TD colspan=2 valign=top style=width:239.4pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'><B>NewBridge Global Ventures, Inc.</B></P>
<P style='font:10pt Times New Roman;margin:0'>(Registrant)</P>
</TD></TR>
<TR><TD valign=top style=width:32.4pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD><TD valign=top style=width:207pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD><TD valign=top style=width:13.5pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD><TD valign=top style=width:225.9pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD></TR>
<TR style=height:3.7pt><TD valign=top style=width:32.4pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD><TD valign=top style=width:207pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>Dated: January 18, 2019&#160;&#160;</P>
</TD><TD valign=top style=width:13.5pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD><TD valign=top style=width:225.9pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>By: &#160;&#160;&#160;&#160;/s/&#160;<I>Robert Bench</I></P>
<P style='font:10pt Times New Roman;margin:0'>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name: &#160;&#160;Robert Bench</P>
<P style='font:10pt Times New Roman;margin:0'>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title: &#160;&#160;&#160;&#160;Principal Executive Officer</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:10pt'>&#160;&#160;</P>
<P style='font:11pt Calibri;margin-top:0pt;margin-bottom:10pt'><FONT style='font-family:Times New Roman'>&#160;</FONT></P>
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "nbgv_8k.htm", "description": "8-K", "secsgml_size_bytes": 17187}]
{"company-data": {"conformed-name": "NewBridge Global Ventures, Inc.", "cik": "0000726293", "assigned-sic": "0100", "irs-number": "841089377", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-11730", "film-number": "19531799"}, "business-address": {"street1": "2545 SANTA CLARA AVENUE", "city": "ALAMEDA", "state": "CA", "zip": "94501", "phone": "801-362-2115"}, "mail-address": {"street1": "2545 SANTA CLARA AVENUE", "city": "ALAMEDA", "state": "CA", "zip": "94501"}, "former-company": [{"former-conformed-name": "NABUfit Global, Inc.", "date-changed": "20160304"}, {"former-conformed-name": "CRYPTOSIGN, INC.", "date-changed": "20150930"}, {"former-conformed-name": "STRATEGABIZ, INC.", "date-changed": "20150210"}]}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 17, 2019
NEWBRIDGE GLOBAL VENTURES, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
0-11730
84-1089377
(State or other jurisdiction
of incorporation)
Commission File
Number
(I.R.S. Employer Identification number)
2545 Santa Clara Avenue
Alameda, CA 94501
(Address of Principal Executive Offices)
801-362-2115
(Registrant's Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01.  Entry into a Material Definitive Agreement
The information furnished in Item 5.02 herein is hereby incorporated by reference into this Item 1.01
Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On January 17, 2019 the Board of Directors of NewBridge Global Ventures, Inc. (the "Company") determined to appoint Dr. John MacKay as Chief Technology Officer ("CTO") of the Company, Patrick P. Tang as Chief Compliance Officer ("CCO") of the Company and Sandra Ribble as Corporate Controller of the Company.
Dr. John A. MacKay in his position as Chief Technology Officer ("CTO") shall be an executive officer of the Company. John is the founder and President of Synergistic Technologies Associates, LLC a consulting company that works with botanical companies to help maximize their total operations based on Six Sigma principles and practices. He also serves as contributing journalist and science editor for Terpenes and Testing Magazine and was the editor of the early issues of Extraction Magazine and now is contributing journalist and scientific advisor.  He has also been appointed the Educator Assistant Professor on the Volunteer Pathway, Department of Pharmacology at the Robert Larner, MD College of Medicines. John A. MacKay earned a B.A. in Chemistry from St. Lawrence University (SLU), and Ph.D. from the University of Vermont (UVM), in Inorganic Chemistry focused on the synthesis of cancer-fighting compounds.  After positions teaching at Davidson College, Lyndon State College and University of Vermont (UVM), John joined Waters Corporation in 1983 and retired in 2017.  His career has included many roles in innovative product development and marketing.  John is widely recognized as scientific expert extraction with an emphasis on the sub and supercritical fluid for extraction and chromatography in the botanical space; he is bringing the synergy from what were disparate technologies together to optimize workflow. Pursuant to his employment agreement, Dr. MacKay shall receive an annual salary of $10,000 per month, a sign-on bonus of 200,000 shares of the Company's common stock, options to acquire 1,000,000 shares of the Company's common stock at an exercise price of $1.00 per share, and will be eligible for annual variable compensation. The foregoing is qualified in its entirety by reference to the employment agreement between Dr. MacKay and the Company which is attached hereto as Exhibit 10.1
Mr. Patrick Tang, in his position of Chief Compliance Officer ("CCO") shall be an executive officer of the Company. Mr. Tang has over 28 years of experience in the business management and operations of public and private companies. Prior to joining NewBridge Global Ventures, Mr. Tang has served as a Sales and Business Development Executive at MacDermidAlpha-Compugraphics, and an Executive Advisor at TCE Group, a contract manufacturing services for microelectronics industry.  From 2016 to 2018, Mr. Tang served as Vice President of Sales and Business Development at Advenira, Inc., a developer of nanocomposite. From 2014 to 2016, he also served as Director of Business Development and Application Engineering at Aculon, Inc, a nanomaterial company focusing on microelectronics, wireless, oil & gas, IoT, and medical devices applications. Prior to Aculon, he served as Director of Product Technology Marketing at JCET, tier 1 semiconductor packaging, assembly and test.  Mr. Tang is a licensed Professional Chemical Engineer and holds an MBA from the University of San Francisco with technical training in chemistry, chemical engineering and microelectronics. Pursuant to his employment agreement, Mr. Tang shall receive a salary of $10,000 per month from March 2019 through December 2019 and $15,000 per month for the twelve months ending December 2020, options to acquire 300,000 shares of the Company's common stock to vest over three years at an exercise price of $1.00 per share, and will be eligible for annual variable compensation. The foregoing is qualified in its entirety by reference to the employment agreement between Mr. Tang and the Company which is attached hereto as Exhibit 10.2
A copy of the Company's press release relating to these changes is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.
Item 9.01.  Financial Statements and Exhibits.
(d)         Exhibits
The exhibits listed below are furnished as Exhibits to this Current Report on Form 8-K.
Exhibit No.
Description
10.1
Employment Agreement with Dr. John MacKay
10.2
Employment Agreement with Patrick T. Tang
99.1
Press Release, dated January 17, 2018
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
NewBridge Global Ventures, Inc.
(Registrant)
Dated: January 18, 2019
By:     /s/
Robert Bench
Name:   Robert Bench
Title:     Principal Executive Officer